👤 Liu, Meiqin

Keywords

🔗 main protease (44) 🔗 etiological agent (62) 🔗 infectious disease (312) 🔗 drug design (36) 🔗 crystal structure (114) 🔗 infectious diseases (94) 🔗 viral replication (258) 🔗 cell-cell fusion (34) 🔗 public health (392) 🔗 amino acid (454) 🔗 human coronavirus (623) 🔗 membrane fusion (105)

Articles (3)

Structure of M(pro) from COVID-19 virus and discovery of its inhibitors.
👤 Jin, Zhenming 👤 Du, Xiaoyu 👤 Xu, Yechun 👤 Deng, Yongqiang 👤 Liu, Meiqin 👤 Zhao, Yao 👤 Zhang, Bing 👤 Li, Xiaofeng 👤 Zhang, Leike 👤 Peng, Chao 👤 Duan, Yinkai 👤 Yu, Jing 👤 Wang, Lin 👤 Yang, Kailin 👤 Liu, Fengjiang 👤 Jiang, Rendi 👤 Yang, Xinglou 👤 You, Tian 👤 Liu, Xiaoce 👤 Yang, Xiuna 👤 Bai, Fang 👤 Liu, Hong 👤 Liu, Xiang 👤 Guddat, Luke W 👤 Xu, Wenqing 👤 Xiao, Gengfu 👤 Qin, Chengfeng 👤 Shi, Zhengli 👤 Jiang, Hualiang 👤 Rao, Zihe 👤 Yang, Haitao ⏰ 2020 📚 Nature
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.
👤 Xia, Shuai 👤 Liu, Meiqin 👤 Wang, Chao 👤 Xu, Wei 👤 Lan, Qiaoshuai 👤 Feng, Siliang 👤 Qi, Feifei 👤 Bao, Linlin 👤 Du, Lanying 👤 Liu, Shuwen 👤 Qin, Chuan 👤 Sun, Fei 👤 Shi, Zhengli 👤 Zhu, Yun 👤 Jiang, Shibo 👤 Lu, Lu ⏰ 2020 📚 Cell Res
Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein.
👤 Xia, Shuai 👤 Zhu, Yun 👤 Liu, Meiqin 👤 Lan, Qiaoshuai 👤 Xu, Wei 👤 Wu, Yanling 👤 Ying, Tianlei 👤 Liu, Shuwen 👤 Shi, Zhengli 👤 Jiang, Shibo 👤 Lu, Lu ⏰ 2020 📚 Cell Mol Immunol